VCEL
NASDAQVericel Corporation
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$34.72+0.30 (+0.87%)
01:30 PM07:45 PM
News · 26 weeks58-69%
2025-12-072026-05-31
Mix2790d
- Insider13(48%)
- SEC Filings7(26%)
- Other5(19%)
- Earnings2(7%)
Latest news
25 items- PRThe Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in medicine. The premise is no longer to put something foreign into the body when tissue is lost. The premise is to give the body the scaffolding, the cues, and the conditions it needs to grow back what was taken — and then have that scaffolding dissolve, leaving only the patient's own living tissue behind.On May 21, 2026, a new Nasdaq ticker put a public-mark
- SECVericel Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Vericel Corp (0000887359) (Filer)
- INSIDERDirector Mclaughlin Kevin F exercised 7,000 shares at a strike of $7.84 and sold $229,775 worth of shares (7,000 units at $32.83) as part of a pre-agreed trading plan (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERDirector Wotton Paul K sold $327,425 worth of shares (10,000 units at $32.74), decreasing direct ownership by 35% to 18,802 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERChief Financial Officer Mara Joseph Anthony Jr sold $202,500 worth of shares (5,000 units at $40.50) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 21,009 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERPrincipal Accounting Officer Siegal Jonathan sold $188,045 worth of shares (4,855 units at $38.73) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 1,118 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- SECSEC Form 10-Q filed by Vericel Corporation10-Q - Vericel Corp (0000887359) (Filer)
- SECVericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vericel Corp (0000887359) (Filer)
- PRVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceTotal Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026 Revenue Guidance Raised by $10 Million to $326 to $336 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Total net revenue growth of 30% to $68.4 millionMACI®
- INSIDERDirector Wotton Paul K converted options into 3,200 shares, increasing direct ownership by 12% to 28,802 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERDirector Zerbe Robert L Md converted options into 3,200 shares, increasing direct ownership by 11% to 32,995 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERDirector Rubino Alan L converted options into 3,200 shares, increasing direct ownership by 5% to 64,194 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERDirector Wright Lisa converted options into 3,200 shares, increasing direct ownership by 25% to 15,851 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERDirector Mclaughlin Kevin F converted options into 3,200 shares, increasing direct ownership by 21% to 18,300 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- INSIDERDirector Hagen Heidi converted options into 3,200 shares, increasing direct ownership by 10% to 35,050 units (SEC Form 4)4 - Vericel Corp (0000887359) (Issuer)
- SECVericel Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Vericel Corp (0000887359) (Filer)
- PRVericel to Report First-Quarter 2026 Financial Results on May 7, 2026CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be availab
- INSIDERSEC Form 4 filed by Hopper Jonathan Mark4 - Vericel Corp (0000887359) (Issuer)
- PRWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesIssued on behalf of Avaí Bio, Inc.USANewsGroup.com News CommentaryVANCOUVER, BC, April 6, 2026 /CNW/ -- The global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has been proving itself for years. What most of these companies still lack is the production backbone to actually deliver at scale: GMP qualified facilities, traceable cell banks, and manufacturing processes that regulators will sign off on. The FDA accelerated the timeline in early 2026 by formalizing flexible manufacturing and quality control oversight for cell and gene therapies, clearing a path that had stalled the jump from clinical validati
- PRMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Vericel reported that the contract is for the procureme
- PRVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridCAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indicatio
- INSIDERSEC Form 4 filed by Rubino Alan L4 - Vericel Corp (0000887359) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vericel CorporationSCHEDULE 13G/A - Vericel Corp (0000887359) (Subject)
- INSIDERSEC Form 4 filed by Hagen Heidi4 - Vericel Corp (0000887359) (Issuer)
- SECSEC Form 144 filed by Vericel Corporation144 - Vericel Corp (0000887359) (Subject)
VCEL FAQ
6 questionsWhat does Vericel Corporation do?
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval...Where does VCEL stock trade?
Vericel Corporation (VCEL) is listed on NASDAQ.What sector and industry is VCEL in?
Vericel Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about VCEL?
Vericel Corporation has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-09-17. Recent price targets range from $3900.00 to $4000.00.What companies are similar to VCEL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VCEL side-by-side with any of them on Quantisnow.How can I track VCEL on Quantisnow?
Quantisnow aggregates Vericel Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VCEL to receive live email and push alerts on every new disclosure.